- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 286368, 10 pages
FOXP3+ T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF Agents
1Department of Internal Medicine, Inflammatory Bowel Disease Unit, Complesso Integrato Columbus, Catholic University,
Largo Gemelli 8, 00168 Rome, Italy
2Department of Gynaecology, Catholic University, Rome, Italy
3Inflammatory Bowel Disease Unit, IRCCS Clinical Institute Humanitas, Rozzano, Milano, Italy
4Department of Paediatric Haematology/Oncology, IRCCS Bambin Gesù Children’s Hospital, Rome, Italy
Received 30 April 2013; Accepted 8 July 2013
Academic Editor: Silvia Gregori
Copyright © 2013 Luisa Guidi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S. Danese, G. Fiorino, and S. Rutella, “Regulatory T-cell therapy for Crohn’s disease: in vivo veritas,” Gastroenterology, vol. 143, no. 5, pp. 1135–1138, 2012.
- D. Dieckmann, H. Plottner, S. Berchtold, T. Berger, and G. Schuler, “Ex vivo isolation and characterization of CD4+CD25+ T cells with regulatory properties from human blood,” The Journal of Experimental Medicine, vol. 193, no. 11, pp. 1303–1310, 2001.
- S. Makita, T. Kanai, S. Oshima et al., “CD4+CD25 bright T cells in human intestinal lamina propria as regulatory cells,” Journal of Immunology, vol. 173, no. 5, pp. 3119–3130, 2004.
- S. Hori, T. Nomura, and S. Sakaguchi, “Control of regulatory T cell development by the transcription factor Foxp3,” Science, vol. 299, no. 5609, pp. 1057–1061, 2003.
- F. Powrie, M. W. Leach, S. Mauze, L. B. Caddle, and R. L. Coffman, “Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice,” International Immunology, vol. 5, no. 11, pp. 1461–1471, 1993.
- P. J. Morrissey, K. Charrier, S. Braddy, D. Liggitt, and J. D. Watson, “CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells,” Journal of Experimental Medicine, vol. 178, no. 1, pp. 237–244, 1993.
- S. Read, V. Malmström, and F. Powrie, “Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation,” The Journal of Experimental Medicine, vol. 192, no. 2, pp. 295–302, 2000.
- C. Mottet, H. H. Uhlig, and F. Powrie, “Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells,” Journal of Immunology, vol. 170, no. 8, pp. 3939–3943, 2003.
- A. Blanco Quirós, E. Arranz Sanz, D. Bernardo Ordiz, and J. A. Garrote Adrados, “From autoimmune enteropathy to the IPEX (immune dysfunction, polyendocrinopathy, enteropathy, X-linked) syndrome,” Allergologia et Immunopathologia, vol. 37, no. 4, pp. 208–215, 2009.
- E. Sgouroudis and C. A. Piccirillo, “Control of type 1 diabetes by CD4+Foxp3+ regulatory T cells: lessons from mouse models and implications for human disease,” Diabetes/Metabolism Research and Reviews, vol. 25, no. 3, pp. 208–218, 2009.
- C. M. Costantino, C. Baecher-Allan, and D. A. Hafler, “Multiple sclerosis and regulatory T cells,” Journal of Clinical Immunology, vol. 28, no. 6, pp. 697–706, 2008.
- A. Kuhn, S. Beissert, and P. H. Krammer, “CD4+CD25+ regulatory T cells in human lupus erythematosus,” Archives of Dermatological Research, vol. 301, no. 1, pp. 71–81, 2009.
- S. Sarkar and D. A. Fox, “Regulatory T cell defects in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 56, no. 3, pp. 710–713, 2007.
- P. Quaglino, M. Ortoncelli, A. Comessatti et al., “Circulating CD4+CD25FOXP3+ T cells are up-regulated by biological therapies and correlate with the clinical response in psoriasis patients,” Dermatology, vol. 219, no. 3, pp. 250–258, 2009.
- P. Desreumaux, A. Foussat, M. Allez, et al., “Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease,” Gastroenterology, vol. 143, no. 5, pp. 1207–1217, 2012.
- V. Leso, L. Leggio, A. Armuzzi, G. Gasbarrini, A. Gasbarrini, and G. Addolorato, “Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update,” European Journal of Gastroenterology and Hepatology, vol. 22, no. 7, pp. 779–786, 2010.
- A. P. Malaviya and A. J. Ostör, “Rheumatoid arthritis and the era of biologic therapy,” Inflammopharmacology, vol. 20, no. 2, pp. 59–69, 2012.
- I. H. Kim, C. E. West, S. G. Kwatra, et al., “Comparative efficacy of biologics in psoriasis: a review,” American Journal of Clinical Dermatology, vol. 13, no. 6, pp. 365–374, 2012.
- M. R. Ehrenstein, J. G. Evans, A. Singh et al., “Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy,” The Journal of Experimental Medicine, vol. 200, no. 3, pp. 277–285, 2004.
- S. Nadkarni, C. Mauri, and M. R. Ehrenstein, “Anti-TNFα therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGFβ,” The Journal of Experimental Medicine, vol. 204, no. 1, pp. 33–39, 2007.
- Z. Li, I. Arijs, G. De Hertogh et al., “Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab,” Inflammatory Bowel Diseases, vol. 16, no. 8, pp. 1299–1310, 2010.
- A. Di Sabatino, P. Biancheri, S. Piconese et al., “Peripheral regulatory T cells and serum transforming growth factor-β: relationship with clinical response to infliximab in Crohn's disease,” Inflammatory Bowel Diseases, vol. 16, no. 11, pp. 1891–1897, 2010.
- G. Boschetti, S. Nancey, F. Sardi, X. Roblin, B. Flourié, and D. Kaiserlian, “Therapy with anti-TNFα antibody enhances number and function of Foxp3+ regulatory T cells in inflammatory bowel diseases,” Inflammatory Bowel Diseases, vol. 17, no. 1, pp. 160–170, 2011.
- J. Grundström, L. Linton, S. Thunberq, et al., “Altered immunoregulatory profile during anti-tumor necrosis factor treatment of patients with inflammatory bowel disease,” Clinical and Experimental Immunology, vol. 169, no. 2, pp. 137–147, 2012.
- C. Veltkamp, M. Anstaett, K. Wahl et al., “Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFα treatment,” Gut, vol. 60, no. 10, pp. 1345–1353, 2011.
- J. Maul, C. Loddenkemper, P. Mundt et al., “Peripheral and intestinal regulatory CD4+ T cells in inflammatory bowel disease,” Gastroenterology, vol. 128, no. 7, pp. 1868–1878, 2005.
- M. Saruta, Q. T. Yu, P. R. Fleshner et al., “Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease,” Clinical Immunology, vol. 125, no. 3, pp. 281–290, 2007.
- N. Holmén, A. Lundgren, S. Lundin et al., “Functional CD4+ regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity,” Inflammatory Bowel Diseases, vol. 12, no. 6, pp. 447–456, 2006.
- I. Ricciardelli, K. J. Lindley, M. Londei, and S. Quaratino, “Anti tumour necrosis-α therapy increases the number of FOXP3 + regulatory T cells in children affected by Crohn's disease,” Immunology, vol. 125, no. 2, pp. 178–183, 2008.
- W. R. Best, J. M. Becktel, J. W. Singleton, and F. Kern Jr., “Development of a Crohn's disease activity index. National cooperative Crohn's disease study,” Gastroenterology, vol. 70, no. 3, pp. 439–444, 1976.
- D. Rachmilewitz, F. Barbier, P. Defrance et al., “Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial,” British Medical Journal, vol. 298, no. 6666, pp. 82–86, 1989.
- G. Bonanno, A. Mariotti, A. Procoli, et al., “Indoleamine 2, 3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma,” Journal of Translational Medicine, vol. 10, pp. 247–263, 2012.
- S. Kugathasan, L. J. Saubermann, L. Smith et al., “Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease,” Gut, vol. 56, no. 12, pp. 1696–1705, 2007.
- J. S. Oh, Y. G. Kim, S. G. Lee et al., “The effect of various disease-modifying anti-rheumatic drugs on the suppressive function of CD4+CD25+ regulatory T cells,” Rheumatology International, vol. 33, no. 2, pp. 381–388, 2013.
- X. Valencia, G. Stephens, R. Goldbach-Mansky, M. Wilson, E. M. Shevach, and P. E. Lipsky, “TNF downmodulates the function of human CD4+ T-regulatory cells,” Blood, vol. 108, no. 1, pp. 253–261, 2006.
- A. Dige, C. L. Hvas, B. Deleuran et al., “Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells,” Scandinavian Journal of Gastroenterology, vol. 46, no. 10, pp. 1206–1214, 2011.
- F. F. Spurio, A. Aratari, G. Margagnoni, M. T. Doddato, and C. Papi, “Early treatment in Crohn's disease: Do we have enough evidence to reverse the therapeutic pyramid?” Journal of Gastrointestinal and Liver Diseases, vol. 21, no. 1, pp. 67–73, 2012.